摘要
骨质疏松症是以骨量减少、骨组织结构损害为特征的慢性疾病,在中老年人群中(尤其在绝经后女性人群中)发病率较高。该病严重威胁患者身心健康,给患者家庭带来沉重负担。临床治疗骨质疏松的西药因不良反应多和价格昂贵等影响了其应用。淫羊藿作为我国传统中药,使用安全、容易获取,被广泛应用于骨科疾病的治疗。前期研究证实,淫羊藿的主要成分淫羊藿苷在治疗骨质疏松症中有良好应用前景,其可通过上调成骨标志物碱性磷酸酶(ALP)、RUNX2、BMP-2等的表达促进成骨细胞、骨髓间充质干细胞(BMSCs)的增殖分化作用,并实现骨再生及骨形成,在这一过程中Wnt/β-catenin、OPG/RANK/RANKL等信号通路发挥重要作用。基于此,本文对淫羊藿苷治疗骨质疏松症的作用及可能机制作一综述。
Osteoporosis is a chronic disease characterized by bone loss and structural damage of bone tissue.It has a high incidence rate in middle-aged and elderly people,especially in postmenopausal women.The disease seriously threatens the physical and mental health of patients and brings heavy burden to their families.Because of its side eff ects and high price,the use of drugs for the treatment of osteoporosis has been aff ected.Epimedium,a traditional Chinese medicine,is safe to use and easy to obtain.It is widely used in the treatment of orthopedic diseases.Previous studies have confi rmed that icariin,the main component of epimedium,has a good application prospect in the treatment of osteoporosis.It can promote the proliferation and diff erentiation of osteoblasts and BMSCs by up regulating the expression of osteogenic markers ALP,RUNX2,BMP-2,etc.,and achieve bone regeneration and bone formation.In this process,Wnt/β-Catenin,OPG/RANK/RANKL and other signaling pathways play an important role.Based on this,this article reviews the eff ect and possible mechanism of icariin on osteoporosis.
作者
朱元超
秦浩添
刘苏
陈奕孝
张耕
廖帅
翁鉴
于斐
曾晖
ZHU Yuan-chao;QIN Hao-tian;LIU Su;CHEN Yi-xiao;ZHANG Geng;LIAO Shuai;WENG Jian;YU Fei;ZENG Hui(Graduate school,Zunyi Medical University,Zunyi Guizhou,563000,China;Department of Bone and Joint,Peking University Shenzhen Hospital,Shenzhen Guangdong,518036,China)
出处
《中华养生保健》
2023年第4期58-62,共5页
CHINESE HEALTH CARE
基金
国家自然科学基金(82172432,82102568,82001319)
骨科生物材料国家地方联合工程研究中心(XMHT20190204007)
深圳市高水平医院建设专项经费资助:高水平“登峰学科建设”(SZXK023)
深圳“医疗卫生三名工程”项目(SZSM201612092)
深圳市科技研发资金项目(Z2021N054,JCYJ20210324110214040)
广东省基础与应用基础研究基金(2021A1515012586)
白求恩·石药骨质疏松科研基金项目(G-X-2020-1107-21)
北京大学深圳医院科研启动金项目(KYQD2021099)。
